bluebird bio, Inc. (BLUE) Dividend History

Company News

• Bluebird Bio Shareholders Get New All-Cash Offer From Private Equity

  Bluebird Bio has amended its definitive agreement with Carlyle and SK Capital Partners, allowing shareholders to choose between $5 cash or $3 plus a $6.84 contingent value right (CVR) per share. The transaction is expected to close promptly after receiving all regulatory approvals.

  Benzinga

  Featured Companies: CG
• EMV POS Terminal Global Strategic Business Report 2025: Market to Double to $20.6 Billion by 2030 - Focus on Compliance with EMV Standards, Advances in User Interface Propels Market Growth

  The global EMV POS terminal market is expected to grow from $10.3 billion in 2023 to $20.6 billion by 2030, driven by increasing adoption of secure payment technologies, rising payment fraud, and advancements in POS systems.

  GlobeNewswire Inc.

  Featured Companies: CTLP GPN
• This Beaten-Down Biotech Stock Just Got Some Good News: Time to Buy?

  CRISPR Therapeutics has received regulatory approvals for its gene-editing medicine Casgevy, but its high cost poses a challenge for accessibility. The Biden administration's plan to help Medicaid patients afford the treatment could expand its reach. CRISPR Therapeutics has a promising pipeline, and its gene-editing platform has been validated, making it a long-term investment opportunity.

  The Motley Fool

  Featured Companies: CRSP VRTX
• Crispr Therapeutics' Strategic Moves Amidst Gene Therapy Challenges (Rating Upgrade)

  CRISPR's gene therapy, Casgevy, faces operational challenges and stiff competition from Lyfgenia. Read why I've upgraded CRSP stock from Sell to Hold.

  Seeking Alpha

  Featured Companies: CRSP VRTX
• bluebird (BLUE) Tops on Q1 Sales, Zynteglo Progresses Well

  bluebird (BLUE) beats sales estimates in the first quarter on increased Zynteglo product revenues. The company is on track with the ongoing launch of its gene therapies.

  Zacks Investment Research

  Featured Companies: CRSP HTGC VRTX